Ad
Thursday, 17 October 2019
AstraZeneca gets FDA priority review for experimental breast cancer drug
Drugmaker AstraZeneca Plc said on Thursday its experimental breast cancer treatment will get a speedy review by the U.S. Food and Drug Administration, with a decision by the health regulator expected in the second quarter of next year.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment